Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease.
Borhani Haghighi
Afshin
A
Safari
Anahid
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008959:Models, Neurological; D009422:Nervous System Diseases / Q000276:immunology / Q000628:therapy*; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019947:Receptors, Interleukin-6; C502936:tocilizumab